H.C. Wainwright downgraded Diffusion Pharmaceuticals (NASDAQ:DFFN) to “neutral” from “buy” without a price target after the company on Nov. 12 announced that it is not moving forward with its two key clinical programs...
Adamis Pharmaceuticals (NASDAQ:ADMP) received a second complete response letter (CRL) from the FDA regarding its ZIMHI high dose naloxone injection product for the treatment of opioid overdose. The FDA issued its first...
Cytokinetics (NASDAQ:CYTK) reported primary results from its Phase 3 GALACTIC-HF trial evaluating omecamtiv mecarbil for the treatment of heart failure. Omecamtiv mecarbil is a novel selective cardiac myosin activator...
Esperion (NASDAQ: ESPR) presented positive pooled results from four Phase 3 NEXLETOL trials at the virtual American Heart Association scientific sessions. NEXLETOL, or bempedoic acid, is a non-statin, low-density...
Albireo Pharma (NASDAQ:ALBO) presented positive results from two Phase 3 trials of odevixibat at the American Association for the Study of Liver Diseases meeting. Odevixibat is an ileal bile acid transport inhibitor...
Annexon (NASDAQ:ANNX) launched a Phase 2 trial evaluating ANX005 for the treatment of Huntington’s disease. ANX005 is a monoclonal antibody designed to inhibit the complement protein, C1q. “Huntington’s disease is a...
Hepion Pharmaceuticals (NASDAQ:HEPA) will present positive findings from an expanded study of CRV431 at The Liver Meeting Digital Experience 2020 on Nov. 13. The poster presentation will review a study in which...
Surface Oncology’s (NASDAQ:SURF) SRF388 received FDA fast track designation for the treatment of hepatocellular carcinoma in patients who have previously been treated with standard therapies. SRF388 is a fully human...
Lineage Cell Therapeutics (NASDAQ:LCTX) completed enrollment in its Phase 1/2a trial evaluating OpRegen for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy. OpRegen is injected into...
SVB Leerink launched coverage of Opthea (NASDAQ:OPT) with an “outperform” rating and $33 price target. The stock closed at $13.19 on Nov. 10. “The basis for our recommendation and valuation is our forecast for revenue...
IntelGenx (TSXV:IGX; OTCQB:IGXT) received a patent from the U.S. Patent and Trademark Office, covering a novel oral film dosage technology platform for modulating the absorption profile of a sublingually- or buccally...
Five Prime Therapeutics (NASDAQ:FPRX) reported positive topline results from its Phase 2 trial evaluating bemarituzumab, in combination with chemotherapy, in patients with fibroblast growth factor receptor 2b-positive...